Outcome evaluation of a structured educational wellness program in patients with severe mental illness

Journal of Clinical Psychiatry

Volumn 70, Issue 10, 2009, Pages 1385-1396

  Lindenmayer, Jean Pierre ^a,c   Khan, Anzalee ^a,b,c   Wance, Deborah ^a   Maccabee, Neta ^c   Kaushik, Sashank ^d   Kaushik, Saurabh ^a,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b FORDHAM UNIVERSITY   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^d Brookdale Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; GLUCOSE; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIABETES MELLITUS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; FEMALE; HEALTH PROGRAM; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC SYNDROME X; OBESITY; OUTCOME ASSESSMENT; PATIENT EDUCATION; PRIORITY JOURNAL; SCORING SYSTEM; WEIGHT CHANGE; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; COMBINED MODALITY THERAPY; COMORBIDITY; CORONARY DISEASE; CURRICULUM; FEMALE; HEALTH PROMOTION; HOSPITALIZATION; HUMANS; MALE; MENTAL DISORDERS; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; PATIENT EDUCATION AS TOPIC; PROGRAM EVALUATION; RISK FACTORS; RISK REDUCTION BEHAVIOR; SEVERITY OF ILLNESS INDEX;

EID: 72849137066     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04740yel     Document Type: Article

References (27)

1. Lindenmayer JP, Nathan AM, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry. 2001;62(suppl 23):30-38. PubMed
2. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-93. PubMed doi:10.2165/00023210-200519001-00001
3. Strassnig M, Ganguli R. Weight loss interventions for patients with schizophrenia. Clin Schizophr Related Psychoses. 2007;1(1):43-53. doi:10.3371/CSRP.1.1.3
4. Menza M, Vreeland B, Minsky S, et al. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry. 2004;65(4):471-477. PubMed
5. Allison DB, Mentore JL, Moonseong H, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686- 1696. PubMed
6. Mauri M, Castrogiovanni S, Simoncini M, et al. Effects of an educational intervention on weight gain in patients treated with antipsychotics. J Clin Psychopharmacol. 2006;26(5):462-466. PubMed doi:10.1097/01.jcp.0000237943.57893. e6 (Pubitemid 44401464)
7. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353(12):1209-1223. PubMed doi:10.1056/NEJMoa051688
8. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003;160(2):290-296. PubMed doi:10.1176/appi.ajp.160.2.290 (Pubitemid 41110454)
9. American Diabetes Association. Standards of medical care in diabetes: 2006. Diabetes Care. 2006;29(suppl 1):S4-S42. PubMed
10. Wu RR, Zhao JP, Jin H, et al. Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial. JAMA. 2008;299(2):185-193. PubMed doi:10.1001/jama.2007.56-b
11. Ganguli R, Vreeland B, Newcomer JW. Monitoring and managing weight gain in the mentally ill [electronic activity]. J Clin Psychiatry. 2007;68(6):e14. http://www.psychiatrist.com/abstracts /abstracts.asp?abstract=200706/0607e14.htm
12. Rotatori AF, Fox R, Wicks A. Weight loss with psychiatric residents in a behavioral self-control program. Psychol Rep. 1980;46(2):483-486. PubMed
13. Littrell KH, Hilligoss NM, Kirshner CD, et al. The effects of an educational intervention on antipsychoticinduced weight gain. J Nurs Scholarsh. 2003;35(3):237-241. PubMed doi:10.1111/j.1547-5069.2003.00237.x
14. Brar JS, Ganguli R, Pandina G, et al. Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2005;66(2):205-212. PubMed (Pubitemid 40314327)
15. Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial. Aust N Z J Psychiatry. 2005;39(6):479-486. PubMed doi:10.1111/j.1440-1614.2005.01607.x (Pubitemid 40932626)
16. Mauri M, Simoncini M, Castrogiovanni S, et al. A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine. Pharmacopsychiatry. 2008;41(1):17-23. PubMed doi:10.1055/s-2007-992148 (Pubitemid 351195888)
17. Eriksson KM, Westborg CJ, Eliasson MC. A randomized trial of lifestyle intervention in primary healthcare for the modification of cardiovascular risk factors. Scand J Public Health. 2006;34(5):453-461. PubMed doi:10.1080/ 14034940500489826
18. Knowler WC, Barrett-Connor E, Fowler SE. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393-403. PubMed doi:10.1056/NEJMoa012512 (Pubitemid 34437694)
19. Weiden PJ, McCrary KJ, Scheifler PL, et al. Team Solutions. Indianapolis, IN: Eli Lilly and Company; 1997. http://www.treatmentteam.com.
20. Vreeland B, Minsky S, Yanos PT, et al. Efficacy of the Team Solutions program for educating patients about illness management and treatment. Psychiatr Serv. 2006;57(6):822-828. PubMed doi:10.1176/appi.ps.57.6.822 (Pubitemid 43846294)
21. Vreeland B, Minsky S, Menza M, et al. A program for managing weight gain associated with atypical antipsychotics. Psychiatr Serv. 2003;54(8):1155-1157. PubMed doi:10.1176/appi.ps.54.8.1155 (Pubitemid 36951518)
22. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications, pt 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med. 1998;15(7):539-553. PubMed doi:10.1002/(SICI)1096-9136(199807)15:7<539::AID- DIA668>3.0.CO;2-S
23. Little R, Yau L. Intent-to-treat analysis in longitudinal studies with dropouts. Biometrics. 1996;52(4):1324-1333. PubMed doi:10.2307/2532847 (Pubitemid 26425283)
24. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Third report of the National Cholesterol Education Program (NCEP). Circulation. 2002;106:3143-3421. PubMed
25. Jean-Baptiste M, Tek C, Liskov E, et al. A pilot study of a weight management program with food provision in schizophrenia. Schizophr Res. 2007;96(1-3):198-205. PubMed doi:10.1016/j.schres.2007.05.022 (Pubitemid 47494625)
26. Zipursky RB, Gu H, Green AI, et al. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br J Psychiatry. 2005;187:537-543. PubMed doi:10.1192/bjp.187.6.537
27. Keefe RS, Eesley CE, Poe MP. Defining a cognitive function decrement in schizophrenia. Biol Psychiatry. 2005;57(6):688-691. PubMed doi:10.1016/j. biopsych.2005.01.003